| Autor: |
Kotlyar MJ; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Krebs M; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany., Solimando AG; Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, 70124 Bari, Italy., Marquardt A; Department of Pathology, Klinikum Stuttgart, 70174 Stuttgart, Germany., Burger M; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Kübler H; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Bargou R; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany., Kneitz S; Physiological Chemistry I, Theodor-Boveri-Institute, Biocenter, University of Würzburg, 97074 Würzburg, Germany., Otto W; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Breyer J; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Vergho DC; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany., Kneitz B; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany., Kalogirou C; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany. |
| Abstrakt: |
(1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC IVC ) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier-containing miR-21-5p, miR-126-3p and miR-221-3p expression-which significantly predicted the cancer-specific survival (CSS) of ccRCC IVC patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC IVC , we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan-Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan-Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC IVC according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC IVC cohort. |
